Archives
-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-10-09
This 2024 case report describes neuroleptic malignant syndrome after standard-dose prochlorperazine in an older man, despite initially unremarkable or only mildly abnormal laboratory findings. Its main contribution is to show why medication history, longitudinal examination, and clinical pattern recognition remain central when laboratory markers do not display the classic severity profile.
-
(+)-Bicuculline Product Overview
2026-10-09
APExBIO lists (+)-Bicuculline (SKU N1592) as a research compound described as a competitive GABAA receptor antagonist. No matched paper evidence was provided, so the overview is limited to documented product identity and conceptual scope.
-
CCL7+ Macrophages and CRC Immunotherapy Resistance
2026-10-08
A 2025 Journal for ImmunoTherapy of Cancer study identifies CCL7-producing tumor-associated macrophages as a potential driver of colorectal cancer resistance to immune checkpoint blockade. By combining myeloid-specific genetic analysis, tumor models, proteomics, RNA sequencing, and flow cytometry, the study links CCL7 to macrophage metabolism and reduced CD8+ T-cell infiltration.
-
Dihydrotestosterone: From AR Signal to Evidence
2026-10-08
Dihydrotestosterone (DHT) is more than an androgen receptor agonist: it is a useful interpretive probe for separating receptor signaling from disease-specific outcomes. This evidence-led analysis connects prostate biology with cancer and neuromuscular models while clarifying what DHT experiments can—and cannot—demonstrate.
-
Berberine, SIRT6-AMPK, and Atrial Fibrillation
2026-10-07
A 2026 study links berberine’s protection against angiotensin II–induced atrial remodeling to activation of SIRT6-AMPK signaling and suppression of NLRP3 inflammasome activity. Its combination of human atrial samples, bioinformatics, a murine AF model, and SIRT6 gain- and loss-of-function experiments strengthens the proposed mechanism while leaving clinical translation unresolved.
-
Lycopene, DON, and ERK-Mediated Gut Protection
2026-10-07
The 2025 study by Cai and colleagues identifies ERK signaling as a mechanistic link between lycopene protection and reduced deoxynivalenol-induced intestinal barrier dysfunction in IPEC-J2 cells. Its findings connect oxidative stress, inflammatory signaling, and NLRP3 inflammasome activation, while also showing that pharmacological ERK activation weakens lycopene-associated protection.
-
miR-4769-3p, USP18/VDAC2, and SSc Adipogenesis
2026-10-06
Tang et al. identify miR-4769-3p as a potential regulator of subcutaneous adipose tissue loss in systemic sclerosis through the USP18/VDAC2 axis. Their patient, mouse, and cell-model evidence connects elevated miR-4769-3p with impaired adipogenesis, while also defining important limits for interpreting a bleomycin-based disease model.
-
Drug Response Metrics in Cancer In Vitro
2026-10-06
Hannah R. Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating proliferative arrest from cell killing, improving interpretation of apoptosis-related drug effects while highlighting the importance of response timing and model context.
-
Naringin, VEGFC, and Hepatic Fibrosis
2026-10-05
A 2026 Phytomedicine study identifies a hepatocyte–macrophage VEGFC pathway that links metabolic liver injury to inflammatory macrophage behavior and fibrosis. Using human data, mouse genetics, pharmacological inhibition, and cell-based models, the work positions VEGFR-3 signaling as a mechanistic contributor to NASH-associated fibrosis while supporting naringin as a pathway-modulating intervention.
-
MK 0893: From Receptor Antagonism to Translation
2026-10-05
MK 0893 is a glucagon receptor antagonist whose value extends beyond nanomolar potency. This evidence-centered analysis connects its allosteric mechanism, cAMP inhibition, animal-model findings, selectivity profile, and translational limitations for type 2 diabetes research.
-
SAR131675: VEGFR-3 Evidence and Research Context
2026-10-04
This source-grounded overview examines SAR131675 as a reported selective ATP-competitive VEGFR-3 inhibitor, emphasizing its proposed relevance to lymphangiogenesis, endothelial signaling, angiogenesis, and tumor models. It separates vendor-reported biochemical and preclinical findings from independently established evidence, compares conceptual applications, and explains limitations involving selectivity, model translation, provenance, and reported metabolic liabilities.
-
Regorafenib in Cancer Biology: Evidence and Limits
2026-10-03
Regorafenib, also known as BAY 73-4506, is a multikinase inhibitor studied across angiogenic and oncogenic signaling models. A 2024 iScience study links its anti-melanoma activity to reduced RRM2 and altered ERK/E2F3 signaling, but the evidence remains preclinical and does not establish clinical efficacy in melanoma.
-
BglII Restriction Endonuclease Workflow
2026-10-02
BglII Restriction Endonuclease provides rapid cleavage of DNA containing the 5′-AGATCT-3′ recognition site, supporting plasmid DNA digestion, PCR product cleavage, and selected genomic DNA workflows. This dossier-based guide explains sequence checks, reaction setup, gel QC, and troubleshooting; the product is for scientific research only and not for diagnostic or medical use.
-
BAY-826 Workflow for Retinal Signaling Studies
2026-10-01
Build mechanism-focused retinal assays with BAY-826, a potent small molecule inhibitor suited to dose-response, hypoxia, and Müller cell–retinal neuron workflows. Pair pharmacological perturbation with Tie-2/PI3K/Akt, PEDF, and viability readouts to distinguish direct signaling effects from glia-mediated neuroprotection.
-
Leptin (116-130), amide, mouse: Assay Strategy
2026-10-01
Leptin (116-130), amide, mouse offers a defined peptide probe for dissecting energy homeostasis, leptin signaling, and immunometabolic responses. This guide translates a recent SIRT6-AMPK/NLRP3 study into better assay controls without overstating what the cardiovascular evidence proves.